AI 聊天
Loading data for MDGL — first visit, this takes a few seconds.

Madrigal Pharmaceuticals, Inc.

MDGL · NasdaqGS · USD

518.17 -21.89 (-4.05%)

收盘价: Sep 15, 2026, 6:32 PM

市值
$11.97B
下次财报日期
Nov 4, 2026

Madrigal Pharmaceuticals, Inc.(MDGL)股价、分析与数据

内在价值

正在加载内在价值…

分析师预测

股票预测 →

分析师预测不可用

12个月目标价 · n/a 位分析师

分析师一致意见: n/a

时间间隔:1D
正在加载K线和信号…

财务表现

查看财务 →

加载中...

最新财报

已公布较预期同比变动
营收$364.3Mn/a+71.17%
每股收益(TTM)-$1.99+$0.24-4.74%

下次财报

开盘前。

预估 · 升级 →

查看财报详情 →

指标

买价
511.93
市值
12B
净利润(TTM)
-325M
-0.99
-13.99
n/a
53.84
市净率(TTM)
22.85
市销率(TTM)
9.32
财报日期
Nov 4, 2026
卖价
512.55
成交量
145,281
20日均量
346,300
开盘价
539.25
前收盘价
540.06
日内区间
513.36 - 539.71
52周区间
393.61 - 615.00
分红
n/a
除息日
n/a

关于 Madrigal Pharmaceuticals, Inc.

查看公司资料 →
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. Biotechnology · Healthcare

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

板块 Healthcare
上市日期 Feb 6, 2007
员工人数 915
交易所 NasdaqGS
股票代码 MDGL